VE-cadherin rev 5′ACCGCCGTCATTGTCTGCCTC3′

E-cadherin forw 5'GAGCCTGAGTCCTGCAGTCC3' 
(2) 
Snail rev 5'CAGTTGAAGATCTTCCGCGAC3' Slug forw 5'GCGAACTGGACACACACACAGTTAT3' (4) Slug rev 5'CCCCAGTGTGAGTTCTAATGTGTCC3' Twist forw 5'CGGGTCATGGCTAACGTG3' (5) Twist rev 5'CAGCTTGCCATCTTGGAGTC3' PAI-1 forw 5'GGGAAAAGGGGCTGTGTGAC3' (6) PAI-1 rev 5'GTACACGGTGTGTGGCTGTC3' MMP-9 forw 5'TCCTACTCTGCCTGCACCACTAAAG3' (7) MMP-9 rev 5'CTGTACCCTTGGTCTGGACAGAAAC3' Alk-5 forw 5'TGTTTCTGCCACCTCTGTAC3' (8) Alk-5 rev 5'GTGCCCTCTGAAATGAAAGG3' Tgfbr2 forw 5'GTGTCCACTTGGATGAGAGC3' (8) Tgfbr2 rev 5'GCGGTGAACAACAGCTACTG3' Smad2 forw 5'CTCCAGTCTTAGTGCCTCGG3' (9) Smad2 rev 5'AACACCAGAATGCAGGTTCC3' 


Table 2 . VE-cadherin immunoreactivity in human mammary carcinoma cells

 2 
	8.	Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad
		signaling pathway support transcriptomic reprogramming during epithelial-
		mesenchymal cell transition. Mol Biol Cell 2005; 16: 1987-2002.
	9.	Bristol-Gould SK, Hutten CG, Sturgis C, Kilen SM, Mayo KE, Woodruff TK. The
		development of a mouse model of ovarian endosalpingiosis. Endocrinology 2005;
		146: 5228-5236.